# Celldex Therapeutics

Source: https://onco.cc/companies/celldex/  
OnCo record `celldex` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Biotech that ran one of the early GPNMB ADCs in triple-negative breast cancer, which failed, and has since pivoted to mast-cell (KIT) antibodies for allergic disease.

## Summary

Glembatumumab vedotin (CDX-011, GPNMB-directed MMAE ADC) did not meet its primary endpoint in the METRIC trial in GPNMB-overexpressing metastatic TNBC (2018). Celldex's lead asset is now barzolvolimab, an anti-KIT antibody in phase 3 for chronic urticaria; its oncology footprint is historical but instructive for ADC target selection.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Tags: failure; adc-history
- HQ: Hampton, NJ
- Type: biotech
- Website: https://www.celldex.com
- Ticker: CLDX

## Sources

- Celldex pipeline: https://celldex.com/pipeline/

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [KIT](https://onco.cc/targets/kit/)
- drugs: [Rindopepimut](https://onco.cc/drugs/rindopepimut/)
- trials: [ACT IV](https://onco.cc/trials/act-iv/)

---
JSON: https://onco.cc/api/v1/entities/celldex.json